presentación de powerpoint - vlpbio · design chimeric virus like particles to stimulate the most...
TRANSCRIPT
![Page 1: Presentación de PowerPoint - VLPBIO · design chimeric virus like particles to stimulate the most adequate response against the target pathology. Translation Chimeric VLPs 4. Ch-VLP](https://reader035.vdocuments.us/reader035/viewer/2022081405/5f0bfa477e708231d4332776/html5/thumbnails/1.jpg)
c1
![Page 2: Presentación de PowerPoint - VLPBIO · design chimeric virus like particles to stimulate the most adequate response against the target pathology. Translation Chimeric VLPs 4. Ch-VLP](https://reader035.vdocuments.us/reader035/viewer/2022081405/5f0bfa477e708231d4332776/html5/thumbnails/2.jpg)
Problem=Opportunity
✓ Reduced efficacy of actual vaccines
✓ Short duration of immunity
✓ No cross-protection against different strains
✓ Biosafety issues
✓ Imperfect costs for end users
Vaccination offers an effective,
inexpensive way to safeguarding the
health and welfare of animals, however
there is still room for innovations
2
![Page 3: Presentación de PowerPoint - VLPBIO · design chimeric virus like particles to stimulate the most adequate response against the target pathology. Translation Chimeric VLPs 4. Ch-VLP](https://reader035.vdocuments.us/reader035/viewer/2022081405/5f0bfa477e708231d4332776/html5/thumbnails/3.jpg)
VP2 protein is a structural protein of
the Infectious Bursitis virus (IBDV)
what naturally autoassemble
forming Virus-Like Particles
Translation
Assembling
process
x60
VLPs
VP2
protein
VP2 gene
Ch-VLP Platform: Technology Basis
3
![Page 4: Presentación de PowerPoint - VLPBIO · design chimeric virus like particles to stimulate the most adequate response against the target pathology. Translation Chimeric VLPs 4. Ch-VLP](https://reader035.vdocuments.us/reader035/viewer/2022081405/5f0bfa477e708231d4332776/html5/thumbnails/4.jpg)
Chimeric
VP2
proteins
Ch-VLP Platform: Technology Basis
Chimeric
VP2 gene
Displaying selected epitopes, we can
design chimeric virus like particles
to stimulate the most adequate
response against the target
pathology.
Translation
Chimeric
VLPs
4
![Page 5: Presentación de PowerPoint - VLPBIO · design chimeric virus like particles to stimulate the most adequate response against the target pathology. Translation Chimeric VLPs 4. Ch-VLP](https://reader035.vdocuments.us/reader035/viewer/2022081405/5f0bfa477e708231d4332776/html5/thumbnails/5.jpg)
Ch-VLP Platform: Technology Basis
5
![Page 6: Presentación de PowerPoint - VLPBIO · design chimeric virus like particles to stimulate the most adequate response against the target pathology. Translation Chimeric VLPs 4. Ch-VLP](https://reader035.vdocuments.us/reader035/viewer/2022081405/5f0bfa477e708231d4332776/html5/thumbnails/6.jpg)
0%
20%
40%
60%
80%
100%
0 10 20 30 40 50 60
Surv
ival
Rat
e (%
)
Time (Days)
Ch-VLP
Epitope
Control
• High Efficiency: Boosted and durable host immune response.
Ch-VLP Platform: Main Advantages
6
![Page 7: Presentación de PowerPoint - VLPBIO · design chimeric virus like particles to stimulate the most adequate response against the target pathology. Translation Chimeric VLPs 4. Ch-VLP](https://reader035.vdocuments.us/reader035/viewer/2022081405/5f0bfa477e708231d4332776/html5/thumbnails/7.jpg)
Antibodies titer
Ant-VP1 Ant-VP2 Ant-VP3
• Differentiating Infected from Vaccinated Animals (DIVA).
• High Efficiency: Boosted and durable host immune response.
Ch-VLP Platform: Main Advantages
7
![Page 8: Presentación de PowerPoint - VLPBIO · design chimeric virus like particles to stimulate the most adequate response against the target pathology. Translation Chimeric VLPs 4. Ch-VLP](https://reader035.vdocuments.us/reader035/viewer/2022081405/5f0bfa477e708231d4332776/html5/thumbnails/8.jpg)
• Biosafety: without genetic material it is not able to autoreplicate.
• Differentiating Infected from Vaccinated Animals (DIVA).
• High Efficiency: Boosted and durable host immune response.
Ch-VLP Platform: Main Advantages
8
![Page 9: Presentación de PowerPoint - VLPBIO · design chimeric virus like particles to stimulate the most adequate response against the target pathology. Translation Chimeric VLPs 4. Ch-VLP](https://reader035.vdocuments.us/reader035/viewer/2022081405/5f0bfa477e708231d4332776/html5/thumbnails/9.jpg)
• High flexibility: Formulation of different Ch-VLPs monocomponents or displaying
different antigens (cellular, humoral or both), consensus sequences, multiple targets…
• Biosafety: without genetic material it is not able to autoreplicate.
• Differentiating Infected from Vaccinated Animals (DIVA).
• High Efficiency: Boosted and durable host immune response.
Ch-VLP Platform: Main Advantages
9
![Page 10: Presentación de PowerPoint - VLPBIO · design chimeric virus like particles to stimulate the most adequate response against the target pathology. Translation Chimeric VLPs 4. Ch-VLP](https://reader035.vdocuments.us/reader035/viewer/2022081405/5f0bfa477e708231d4332776/html5/thumbnails/10.jpg)
• High flexibility: Formulation of different Ch-VLPs monocomponents or displaying
different antigens (cellular, humoral or both), consensus sequences, multiple targets…
• Biosafety: without genetic material it is not able to autoreplicate.
• Low-cost production system: Already validated in several hosts
• Differentiating Infected from Vaccinated Animals (DIVA).
• High Efficiency: Boosted and durable host immune response.
Ch-VLP Platform: Main Advantages
10
![Page 11: Presentación de PowerPoint - VLPBIO · design chimeric virus like particles to stimulate the most adequate response against the target pathology. Translation Chimeric VLPs 4. Ch-VLP](https://reader035.vdocuments.us/reader035/viewer/2022081405/5f0bfa477e708231d4332776/html5/thumbnails/11.jpg)
Product Development Roadmap
Preliminary Process
DevelopmentPreliminary
immunogenicity/efficacy
Regulatory Studies Registration
CommercializationIdeaFMD TeStop PRRSV IBDVBVDVPCV2
Prototypes generation
Our Ch-VLPs are ideal vehicles to generate vaccines
against animal pathologies in which protection is
dependent on one or few well-known epitopes
ASFV, Horse Flu, Pet
oncology, etc.
Potential New
Developments
VLPbio Products Portfolio
11
![Page 12: Presentación de PowerPoint - VLPBIO · design chimeric virus like particles to stimulate the most adequate response against the target pathology. Translation Chimeric VLPs 4. Ch-VLP](https://reader035.vdocuments.us/reader035/viewer/2022081405/5f0bfa477e708231d4332776/html5/thumbnails/12.jpg)
Our products portfolio already contents products against the main
impacting diseases in the veterinary field, targeting a global market
of >1 Billion of Euros.
New vaccines development against the most impacting diseases
- Well recognized and challenging diseases
- Globally distributed diseases
- Competitive landscape
VLPbio Target Market
12
![Page 13: Presentación de PowerPoint - VLPBIO · design chimeric virus like particles to stimulate the most adequate response against the target pathology. Translation Chimeric VLPs 4. Ch-VLP](https://reader035.vdocuments.us/reader035/viewer/2022081405/5f0bfa477e708231d4332776/html5/thumbnails/13.jpg)
Thank you
VLPbio is a technological company that provide a first-class technology for the development of
new vaccines with differentiating properties to be successfully applied in animal health
The company has a strong and diversified portfolio of products on development for the most
important diseases not properly covered.
To Conclude
13